In 1993, the first disease-modifying therapy (DMT) specifically for relapsing-remitting multiple sclerosis (RRMS) was introduced, and an untreatable disease became treatable. The US Food and Drug Administration now has approved 14 DMTs in 8 classes with different mechanisms of action, administration routes, and side effects.1 This therapeutic palette allows neurologists to control RRMS in most patients.
US health insurance is an obstacle to disease-modifying treatments in MS
PATTI, Francesco
2016-01-01
Abstract
In 1993, the first disease-modifying therapy (DMT) specifically for relapsing-remitting multiple sclerosis (RRMS) was introduced, and an untreatable disease became treatable. The US Food and Drug Administration now has approved 14 DMTs in 8 classes with different mechanisms of action, administration routes, and side effects.1 This therapeutic palette allows neurologists to control RRMS in most patients.File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
00006114-201607260_US health insurance.pdf
solo gestori archivio
Tipologia:
Versione Editoriale (PDF)
Dimensione
85.46 kB
Formato
Adobe PDF
|
85.46 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.